Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Adenocarcinoma: early-phase trial registry
45 of 100 indexed Prostate Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #136 of 28,707 conditions by registered trial count.
100 US clinical trials · 45 currently recruiting · #136 of 28,707 conditions by registered trial count
Prostate Adenocarcinoma: 100 US clinical trials tracked, 45 recruiting.
Prostate Adenocarcinoma is the subject of 100 registered US clinical trials on ClinicalTrials.gov, 45 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 64 in Phase 1-2 (earlier-stage). The most active sponsor is Jonsson Comprehensive Cancer Center, running 9 of these trials.
Enrollment posture brief
Registry condition prostate-adenocarcinoma
OPEN 45 | RECR 45% | LATE 9 | EARLY 64 | RANK #136 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Germ Cell Tumor (45% recruiting · 20 trials)
Prostate Adenocarcinoma lists 45 open slots (45% of 100 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Adenocarcinoma is recruiting above its size-band peers.
45 of 100 indexed trials (45%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Adenocarcinoma trials is spread across many organizations.
Jonsson Comprehensive Cancer Center accounts for 9 of 100 trials (9%). 50 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Adenocarcinoma enrolment sits around 78 participants.
Median target enrolment is 78 among the 100 trials that report a genuine target (sentinel values excluded). 59 of those (59%) plan for fewer than 100 participants.
-
Prostate Adenocarcinoma research is mostly interventional.
91 interventional and 9 observational studies make up this index (91% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
100 total, page 2 of 2
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial
Jonsson Comprehensive Cancer Center
NCT04624256
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
Profound Medical
NCT05027477
CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study
Jonsson Comprehensive Cancer Center
NCT04384770
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Stanford University
NCT02346253
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
NCT04777071
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Emory University
NCT03762759
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
City of Hope Medical Center
NCT04519879
Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam
M.D. Anderson Cancer Center
NCT04286386
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
H. Lee Moffitt Cancer Center and Research Institute
NCT04300855
CyberKnife Dose Escalation Prostate Cancer Trial
Crozer-Keystone Health System
NCT03822494
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
Jonsson Comprehensive Cancer Center
NCT05496959
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
Mayo Clinic
NCT01953640
A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer
Mayo Clinic
NCT04190446
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
NCT03821792
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Xiao X. Wei, MD
NCT04126070
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT04030338
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
M.D. Anderson Cancer Center
NCT03412396
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
Andrew McDonald
NCT04743934
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Wake Forest University Health Sciences
NCT03246347
MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
University of Miami
NCT01411345
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT05751434
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
National Cancer Institute (NCI)
NCT04530552
Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer
M.D. Anderson Cancer Center
NCT05055843
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
NCT03361735
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
Emory University
NCT05779943
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
University of Utah
NCT03796767
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
Alessa Therapeutics
NCT04943536
Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer
M.D. Anderson Cancer Center
NCT04985565
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Roswell Park Cancer Institute
NCT03899987
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
Beth Israel Deaconess Medical Center
NCT05683964
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
NCT05960578
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
Emory University
NCT06105918
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
Jonsson Comprehensive Cancer Center
NCT02940262
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT04050215
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
NRG Oncology
NCT03860961
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
Jonsson Comprehensive Cancer Center
NCT03368547
C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma
Phoenix Molecular Imaging
NCT01530269
Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation
Roswell Park Cancer Institute
NCT00887432
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Andrei Iagaru
NCT02624518
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
NCT00170157
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
Wake Forest University Health Sciences
NCT01985828
Tivantinib in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT01519414
Fluorescent Imaging of Nerves With Illuminare-1 During Surgery
Memorial Sloan Kettering Cancer Center
NCT04983862
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT03204812
An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
M.D. Anderson Cancer Center
NCT04978675
Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer
Ohio State University Comprehensive Cancer Center
NCT03654638
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NCT04037254
Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer
National Cancer Institute (NCI)
NCT01325311
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Pedro Barata, MD, MSc
NCT06312670
CCRO044: Quality of Life Assessments Associated With a Physician Communication Intervention for Prostate Cancer Patients
University of California, Davis
NCT03780023
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 50 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Adenocarcinoma page
100 registered trials, 45 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 45 Prostate Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jonsson Comprehensive Cancer Center sponsors the most Prostate Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Jonsson Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Adenocarcinoma condition card totals 100 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.